Literature DB >> 18775916

Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesis.

Seung Bae Rho1, Seung Myung Dong, Sokbom Kang, Sang-Soo Seo, Chong Woo Yoo, Dong Ock Lee, Jong Soo Woo, Sang-Yoon Park.   

Abstract

Insulin-like growth factor-binding protein-5 (IGFBP-5) is one of the six members of IGFBP family, important for cell growth control, induction of apoptosis and other IGF-stimulated signaling pathways. In this study, we focused on characterizing the specific function of IGFBP-5 as novel antiangiostatic factor. Overexpression of IGFBP-5 suppressed the tube formation as well as the biological functions of angiostatic activity in vivo. This result is due to the reduced expressions of phosphorylated protein kinase B and phosphorylated endothelial NO synthase, which plays important roles in the regulation of angiogenesis when stimulated by vascular endothelial growth factor. Further, IGFBP-5 expression prevented tumor growth and inhibited tumor vascularity in a xenograft model of human ovarian cancer. These results are the first evidence showing that IGFBP-5 plays a role as tumor suppressor by inhibiting angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18775916     DOI: 10.1093/carcin/bgn206

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  21 in total

Review 1.  The insulin-like growth factor system in cancer.

Authors:  S John Weroha; Paul Haluska
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

2.  Using distance covariance for improved variable selection with application to learning genetic risk models.

Authors:  Jing Kong; Sijian Wang; Grace Wahba
Journal:  Stat Med       Date:  2015-01-29       Impact factor: 2.373

3.  Insulin-Like Growth Factor Binding Protein-2 Promotes Adhesion of Endothelial Progenitor Cells to Endothelial Cells via Integrin α5β1.

Authors:  Nianping Feng; Zhuo Zhang; Zhengfei Wang; Haihong Zheng; Fujun Qu; Xijun He; Chunlai Wang
Journal:  J Mol Neurosci       Date:  2015-06-16       Impact factor: 3.444

4.  Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.

Authors:  Prakash Chinnaiyan; Sajeel Chowdhary; Lisa Potthast; Antony Prabhu; Ya-Yu Tsai; Bhaswati Sarcar; Soumen Kahali; Steven Brem; H Michael Yu; Amyn Rojiani; Ryan Murtagh; Edward Pan
Journal:  Neuro Oncol       Date:  2011-10-25       Impact factor: 12.300

Review 5.  Growth hormone, the insulin-like growth factor axis, insulin and cancer risk.

Authors:  Peter E Clayton; Indraneel Banerjee; Philip G Murray; Andrew G Renehan
Journal:  Nat Rev Endocrinol       Date:  2010-10-19       Impact factor: 43.330

6.  Association between a functional polymorphism (-1195T>C) in the IGFBP5 promoter and head and neck cancer risk.

Authors:  Jiangong Niu; Yu-Jing Huang; Sheng Wei; Zhensheng Liu; Li-E Wang; Shine Chang; Robert M Chamberlain; Adel K El-Naggar; Erich M Sturgis; Qingyi Wei
Journal:  Head Neck       Date:  2010-10-14       Impact factor: 3.147

7.  Gene expression profile and genomic alterations in colonic tumours induced by 1,2-dimethylhydrazine (DMH) in rats.

Authors:  Angelo Pietro Femia; Cristina Luceri; Simona Toti; Augusto Giannini; Piero Dolara; Giovanna Caderni
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

Review 8.  Role of insulin-like growth factor-binding proteins in the pathophysiology and tumorigenesis of gastroesophageal cancers.

Authors:  Manoj K Kashyap
Journal:  Tumour Biol       Date:  2015-09-14

Review 9.  An ocular view of the IGF-IGFBP system.

Authors:  Dung V Nguyen; Sergio Li Calzi; Lynn C Shaw; Jennifer L Kielczewski; Hannah E Korah; Maria B Grant
Journal:  Growth Horm IGF Res       Date:  2013-04-08       Impact factor: 2.372

10.  Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer.

Authors:  Marie-Claude Beauchamp; Amber Yasmeen; Ariane Knafo; Walter H Gotlieb
Journal:  J Oncol       Date:  2010-01-05       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.